Outro estudo randomizado mostrou que o plasma convalescente não beneficia pacientes internados com Covid-19.

Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia: A Randomized Clinical Trial – JAMA Network Open

Conteúdos relacionados:

M-A: Convalescent plasma does not reduce mortality in COVID-19.

RCT: Another study shows convalescent plasma does not improve outcomes in critically ill patients with Covid-19.

RCT: Convalescent plasma does not improve outcomes and may be harmful to hospitalized patients with COVID-19.

NIH study shows no significant benefit of convalescent plasma for COVID-19 outpatients with early symptoms.

M-A: Convalescent plasma is safe but does not improve outcomes in the treatment of COVID-19.

RECOVERY Trial: No benefit from convalescent plasma in patients admitted to hospital with COVID-19.

Comentário no Twitter

The TSUNAMI RCT showed that high-titer convalescent plasma (CP) did not reduce the risk of severe respiratory failure or death in hospitalized patients with #COVID19 pneumonia. https://t.co/4q0S2AtfMj

— JAMA Network Open (@JAMANetworkOpen) November 29, 2021